Literature DB >> 3900095

Butyrate enhances the synthesis of interphotoreceptor retinoid-binding protein (IRBP) by Y-79 human retinoblastoma cells.

A P Kyritsis, B Wiggert, L Lee, G J Chader.   

Abstract

The synthesis and secretion of interphotoreceptor retinoid-binding protein (IRBP) from Y-79 human retinoblastoma cells was investigated using immunocytochemistry and SDS-polyacrylamide gel electrophoresis. Indirect immunofluorescence of cells growing in monolayer culture for 11 and 13 days showed no significant IRBP staining although by SDS-polyacrylamide gel electrophoresis, a small amount of IRBP was detected in the culture medium, suggesting synthesis and extracellular secretion. Butyrate (2mM) treatment of cells starting on the eighth day of culture resulted in a dramatic increase of IRBP fluorescence 3-5 days after treatment. Treatment of cells in all conditions with 1 microM monensin for 3 h showed concentration of IRBP in the Golgi apparatus of about 10-20% of cells as proved by a double immunofluorescent technique, employing anti-IRBP antibody and wheat-germ agglutinin. Incubation of cells with either radiolabeled amino acids or glucosamine followed by analysis of cell cytosol and culture medium by SDS-polyacrylamide gel electrophoresis also confirmed that 1) IRBP is synthesized by the Y-79 cells and secreted into the medium and 2) its production is markedly increased by butyrate treatment. The enhancement of IRBP synthesis by butyrate suggests biochemical differentiation of Y-79 cells possibly into photoreceptor-like cells and offers a new system for studying the properties of this unique retinoid-binding protein and of factors that control its synthesis and secretion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3900095     DOI: 10.1002/jcp.1041240210

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  Laminin-induced retinoblastoma cell differentiation: possible involvement of a 100-kDa cell-surface laminin-binding protein.

Authors:  A Albini; D M Noonan; A Melchiori; G F Fassina; M Percario; S Gentleman; J Toffenetti; G J Chader
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Hypomethylation of the interphotoreceptor retinoid-binding protein (IRBP) promotor and first exon is linked to expression of the gene.

Authors:  A Albini; J Toffenetti; Z Zhu; G J Chader; D M Noonan
Journal:  Nucleic Acids Res       Date:  1990-09-11       Impact factor: 16.971

3.  Differentiation of Y79 cells induced by prolonged exposure to insulin.

Authors:  R Vento; M Giuliano; M Lauricella; M Carabillò; H Main; E Gerbino; G Tesoriere
Journal:  Mol Cell Biochem       Date:  1997-05       Impact factor: 3.396

4.  Differentiation of human retinoblastoma in vitro into cell types with characteristics observed in embryonal or mature retina.

Authors:  M Tsokos; A P Kyritsis; G J Chader; T J Triche
Journal:  Am J Pathol       Date:  1986-06       Impact factor: 4.307

5.  Cell-specific DNA methylation patterns of retina-specific genes.

Authors:  Shannath L Merbs; Miriam A Khan; Laszlo Hackler; Verity F Oliver; Jun Wan; Jiang Qian; Donald J Zack
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

Review 6.  In vitro Model Systems for Studies Into Retinal Neuroprotection.

Authors:  Yu Zhu; Bowen Cao; Arianna Tolone; Jie Yan; Gustav Christensen; Blanca Arango-Gonzalez; Marius Ueffing; François Paquet-Durand
Journal:  Front Neurosci       Date:  2022-07-07       Impact factor: 5.152

7.  Novobiocin-induced anti-proliferative and differentiating effects in melanoma B16.

Authors:  J Nordenberg; D Albukrek; T Hadar; A Fux; L Wasserman; A Novogrodsky; Y Sidi
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

8.  Biochemical and ultrastructural alterations accompany the anti-proliferative effect of butyrate on melanoma cells.

Authors:  J Nordenberg; L Wasserman; A Peled; Z Malik; K H Stenzel; A Novogrodsky
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.